New efforts in therapeutic methods, such as the targeted delivery of siRNA [47,48] or the use of extracellular vesicles as drug delivery systems [49], may allow us to selectively reduce NAMPT expression in IDH1R132H glioma and might be worth investigating in future studies. Here, NAMPT is linked to central nervous system cancer.